DOCSLIB.ORG

Cancer Facts & Figures 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cancer Facts & Figures 2018 Cancer Facts & Figures 2018 WA 36,170 NH MT VT 8,080 ME ND 6,080 3,840 8,600 4,110 MN OR 31,270 21,520 ID MA 8,450 SD WI NY 37,130 5,100 33,340 110,800 WY MI 2,780 56,590 RI 5,920 IA PA CT 21,240 NV NE 17,630 80,960 14,060 10,320 OH NJ 53,260 UT IL IN 68,470 10,950 66,330 37,250 CA CO WV DE 6,110 178,130 25,570 VA KS MO 12,110 MD 33,810 KY 42,420 15,400 35,520 25,990 DC 3,260 NC TN 55,130 AZ OK 36,760 34,740 NM 19,030 AR SC 9,730 16,130 30,450 MS AL GA 18,130 27,830 56,920 TX 121,860 LA 25,080 AK 3,550 FL 135,170 US 1,735,350 PR HI N/A 6,280 Estimated numbers of new cancer cases for 2018, excluding basal cell and squamous cell skin cancers and in situ carcinomas except urinary bladder. Estimates are not available for Puerto Rico. Note: State estimates are offered as a rough guide and should be interpreted with caution. State estimates may not add to US total due to rounding. Special Section: Ovarian Cancer see page 28 Contents Basic Cancer Facts 1 Figure S3. Ovarian Cancer Incidence and Mortality Rates by Race and Ethnicity, US, 2010-2014 30 Figure 1. Trends in Age-adjusted Cancer Death Rates by Site, Males, US, 1930-2015 2 Figure S4. Epithelial Ovarian Cancer Incidence Rates by Age and Race, US, 2010-2014 31 Figure 2. Trends in Age-adjusted Cancer Death Rates by Site, Females, US, 1930-2015 3 Figure S5. Age-adjusted Ovarian Cancer Mortality Rates by Age Group and Race/Ethnicity, 1975-2015 32 Table 1. Estimated Number of New Cancer Cases and Deaths by Sex, US, 2018 4 Table S2. Relative Risks for Established Ovarian Cancer Risk Factors 34 Table 2. Estimated Number of New Cases for Selected Cancers by State, US, 2018 5 Figure S6. Stage Distribution (%) for Ovarian Cancer by Histology, US, 2007-2013 36 Table 3. Estimated Number of Deaths for Selected Cancers by State, US, 2018 6 Table S3. Five-year Cause-specific Survival Rates (%) for Ovarian Cancer by Stage at Diagnosis and Race/Ethnicity, Table 4. Incidence Rates for Selected Cancers by State, US, 2007-2013 37 US, 2010-2014 7 Table S4. Five-year Relative Survival Rates (%) for Ovarian Table 5. Death Rates for Selected Cancers by State, Cancer by Stage at Diagnosis and Histology, US, 2007-2013 37 US, 2011-2015 8 Tobacco Use 44 Selected Cancers 9 Figure 4. Proportion of Cancer Deaths Attributable to Figure 3. Leading Sites of New Cancer Cases and Deaths – Cigarette Smoking in Adults 30 Years and Older, US, 2014 45 2018 Estimates 10 Table 6. Probability (%) of Developing Invasive Cancer Nutrition & Physical Activity 48 during Selected Age Intervals by Sex, US, 2012-2014 14 Table 7. Trends in 5-year Relative Survival Rates (%) Cancer Disparities 52 by Race, US, 1975-2013 18 Table 9. Incidence and Mortality Rates for Selected Cancers Table 8. Five-year Relative Survival Rates (%) by Stage by Race and Ethnicity, US, 2010-2015 54 at Diagnosis, US, 2007-2013 21 The Global Cancer Burden 55 Special Section: Ovarian Cancer 28 The American Cancer Society 57 Figure S1. Female Reproductive Anatomy 28 Figure S2. Distribution (%) of Major Types of Ovarian Sources of Statistics 68 Cancer by Race/Ethnicity, 2010-2014 29 American Cancer Society Recommendations for the Early Table S1. Age-specific Probability of Developing Ovarian Detection of Cancer in Average-risk Asymptomatic People 71 Cancer for US Women 30 Global Headquarters: American Cancer Society Inc. 250 Williams Street, NW, Atlanta, GA 30303-1002 This publication attempts to summarize current scientific information about cancer. 404-320-3333 ©2018, American Cancer Society, Inc. All rights reserved, Except when specified, it does not represent the official policy of the American Cancer Society. including the right to reproduce this publication or portions thereof in any form. Suggested citation: American Cancer Society. Cancer Facts & Figures 2018. For written permission, address the Legal department of the American Cancer Society, 250 Williams Street, NW, Atlanta: American Cancer Society; 2018. Atlanta, GA 30303-1002. genitalia, may also result in the early detection of cancer. Basic Cancer Facts For complete cancer screening guidelines, see page 71. What Is Cancer? How Many People Alive Today Have Cancer is a group of diseases characterized by the Ever Had Cancer? uncontrolled growth and spread of abnormal cells. If the More than 15.5 million Americans with a history of spread is not controlled, it can result in death. Although cancer were alive on January 1, 2016. Some of these the reason why the disease develops remains unknown individuals were diagnosed recently and are still for many cancers, particularly those that occur during undergoing treatment, while most were diagnosed many childhood, there are many known cancer causes, years ago and have no current evidence of cancer. including lifestyle factors, such as tobacco use and excess body weight, and non-modifiable factors, such as inherited genetic mutations, hormones, and immune How Many New Cases and Deaths Are conditions. These risk factors may act simultaneously or Expected to Occur in 2018? in sequence to initiate and/or promote cancer growth. About 1.7 million new cancer cases are expected to be diagnosed in 2018 (Table 1, page 4). This estimate does not Can Cancer Be Prevented? include carcinoma in situ (noninvasive cancer) of any site except urinary bladder, nor does it include basal cell or A substantial proportion of cancers could be prevented, squamous cell skin cancers because these are not required including all cancers caused by tobacco use and other to be reported to cancer registries. Table 2 (page 5) unhealthy behaviors. According to a recent study by provides estimated new cancer cases in 2018 by state. American Cancer Society epidemiologists, at least 42% of newly diagnosed cancers in the US – about 729,000 cases About 609,640 Americans are expected to die of cancer in 2018 – are potentially avoidable, including 19% that are in 2018 (Table 1, page 4), which translates to about 1,670 caused by smoking and 18% that are caused by a deaths per day. Cancer is the second most common cause combination of excess body weight, physical inactivity, of death in the US, exceeded only by heart disease. Table 3 excess alcohol consumption, and poor nutrition. Certain (page 6) provides estimated cancer deaths by state in 2018. cancers caused by infectious agents, such as human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV), and Helicobacter pylori (H. pylori), could be How Much Progress Has Been Made prevented through behavioral changes, vaccination, or against Cancer? treatment of the infection. Many of the more than 5 Cancer death rates are the best measure of progress million skin cancer cases that are diagnosed annually against cancer because they are less affected by detection could be prevented by protecting skin from excessive sun practices than incidence and survival. The overall age- exposure and not using indoor tanning devices. adjusted cancer death rate rose during most of the 20th century mainly because of the tobacco epidemic, peaking Screening can help prevent colorectal and cervical cancers in 1991 at 215 cancer deaths per 100,000 people. As of by allowing for the detection and removal of precancerous 2015, the rate had dropped to 159 per 100,000 (a decline of lesions. Screening also offers the opportunity to detect 26%) because of reductions in smoking, as well as some cancers early, when treatment is more likely to be improvements in early detection and treatment. This successful. Screening is known to help reduce mortality decline translates into more than 2.3 million fewer for cancers of the breast, colon, rectum, cervix, and lung cancer deaths from 1991 to 2015, progress that has been (among long-term current or former heavy smokers). In driven by rapid declines in death rates for the four most addition, a heightened awareness of changes in certain common cancer types – lung, colorectal, breast, and parts of the body, such as the breast, skin, mouth, eyes, or prostate (Figure 1, page 2 and Figure 2, page 3). Cancer Facts & Figures 2018 1 Do Cancer Incidence and Death Rates Relative risk is the strength of the relationship between Vary by State? exposure to a given risk factor and cancer. It is measured by comparing cancer occurrence in people with a certain Tables 4 (page 7) and 5 (page 8) provide average annual exposure or trait to cancer occurrence in people without incidence (new diagnoses) and death rates for selected this characteristic. For example, men and women who cancer types by state. The variation by state is largest for smoke are about 25 times more likely to develop lung lung cancer, reflecting historical and recent differences cancer than nonsmokers, so their relative risk of lung in smoking prevalence. cancer is 25. Most relative risks are not this large. For example, women who have a mother, sister, or daughter Who Is at Risk of Developing Cancer? with a history of breast cancer are about twice as likely to develop breast cancer as women who do not have this Cancer usually develops in older people; 87% of all family history; in other words, their relative risk is about cancers in the United States are diagnosed in people 50 2. For most types of cancer, risk is higher with a family years of age or older.
Load more

Recommended publications
  • Flight Attendant Medical Research Institute Eleventh Scientific Symposium
    FLIGHT ATTENDANT MEDICAL RESEARCH INSTITUTE PUBLICATIONS AND PRESENTATIONS 2002-2013 Table of Contents Table of Contents................................................................................................................ 2 2013..................................................................................................................................... 4 Publications 2013............................................................................................................ 4 Presentations and Abstracts 2013 ................................................................................... 8 Book Chapters, etc., 2013............................................................................................. 11 2012................................................................................................................................... 12 Publications 2012.......................................................................................................... 12 Presentations and Abstracts 2012 ................................................................................. 34 Book Chapters, etc., 2012............................................................................................. 45 2011................................................................................................................................... 46 Publications 2011.......................................................................................................... 46 Presentations and Abstracts 2011 ................................................................................
    [Show full text]
  • Bladder Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis
    cancer.org | 1.800.227.2345 Bladder Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis Finding cancer early, when it's small and hasn't spread, often allows for more treatment options. Some early cancers may have signs and symptoms that can be noticed, but that's not always the case. ● Can Bladder Cancer Be Found Early? ● Bladder Cancer Signs and Symptoms ● Tests for Bladder Cancer Stages and Outlook (Prognosis) After a cancer diagnosis, staging provides important information about the extent (amount) of cancer in the body and the likely response to treatment. ● Bladder Cancer Stages ● Survival Rates for Bladder Cancer Questions to Ask About Bladder Cancer Here are some questions you can ask your cancer care team to help you better understand your cancer diagnosis and treatment options. ● Questions To Ask About Bladder Cancer 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Can Bladder Cancer Be Found Early? Bladder cancer can sometimes be found early -- when it's small and hasn't spread beyond the bladder. Finding it early improves your chances that treatment will work. Screening for bladder cancer Screening is the use of tests or exams to look for a disease in people who have no symptoms. At this time, no major professional organizations recommend routine screening of the general public for bladder cancer. This is because no screening test has been shown to lower the risk of dying from bladder cancer in people who are at average risk. Some providers may recommend bladder cancer tests for people at very high risk, such as: ● People who had bladder cancer before ● People who had certain birth defects of the bladder ● People exposed to certain chemicals at work Tests that might be used to look for bladder cancer Tests for bladder cancer look for different substances and/or cancer cells in the urine.
    [Show full text]
  • Meat, Fish and Dairy Products and the Risk of Cancer: a Summary Matrix 7 2
    Meat, fish and dairy products and the risk of cancer 2018 Contents World Cancer Research Fund Network 3 Executive summary 5 1. Meat, fish and dairy products and the risk of cancer: a summary matrix 7 2. Summary of Panel judgements 9 3. Definitions and patterns 11 3.1 Red meat 11 3.2 Processed meat 12 3.3 Foods containing haem iron 13 3.4 Fish 13 3.5 Cantonese-style salted fish 13 3.6 Grilled (broiled) or barbecued (charbroiled) meat and fish 14 3.7 Dairy products 14 3.8 Diets high in calcium 15 4. Interpretation of the evidence 16 4.1 General 16 4.2 Specific 16 5. Evidence and judgements 27 5.1 Red meat 27 5.2 Processed meat 31 5.3 Foods containing haem iron 35 5.4 Fish 36 5.5 Cantonese-style salted fish 37 5.6 Grilled (broiled) or barbecued (charbroiled) meat and fish 40 5.7 Dairy products 41 5.8 Diets high in calcium 51 5.9 Other 52 6. Comparison with the 2007 Second Expert Report 52 Acknowledgements 53 Abbreviations 57 Glossary 58 References 65 Appendix 1: Criteria for grading evidence for cancer prevention 71 Appendix 2: Mechanisms 74 Our Cancer Prevention Recommendations 79 2 Meat, fish and dairy products and the risk of cancer 2018 WORLD CANCER RESEARCH FUND NETWORK Our Vision We want to live in a world where no one develops a preventable cancer. Our Mission We champion the latest and most authoritative scientific research from around the world on cancer prevention and survival through diet, weight and physical activity, so that we can help people make informed choices to reduce their cancer risk.
    [Show full text]
  • Medical Oncology and Breast Cancer
    The Breast Center Smilow Cancer Hospital 20 York Street, North Pavilion New Haven, CT 06510 Phone: (203) 200-2328 Fax: (203) 200-2075 MEDICAL ONCOLOGY Treatment for breast cancer is multidisciplinary. The primary physicians with whom you may meet as part of your care are the medical oncologist, the breast surgeon, and often the radiation oncologist. A list of these specialty physicians will be provided to you. Each provider works with a team of caregivers to ensure that every patient receives high quality, personalized, breast cancer care. The medical oncologist specializes in “systemic therapy”, or medications that treat the whole body. For women with early stage breast cancer, systemic therapy is often recommended to provide the best opportunity to prevent breast cancer from returning. SYSTEMIC THERAPY Depending on the specific characteristics of your cancer, your medical oncologist may prescribe systemic therapy. Systemic therapy can be hormone pills, IV chemotherapy, antibody therapy (also called “immunotherapy”), and oral chemotherapy; sometimes patients receive more than one type of systemic therapy. Systemic therapy can happen before surgery (called “neoadjuvant therapy”) or after surgery (“adjuvant therapy”). If appropriate, your breast surgeon and medical oncologist will discuss the benefits of neoadjuvant and adjuvant therapy with you. As a National Comprehensive Cancer Network (NCCN) Member Institution, we are dedicated to following the treatment guidelines that have been shown to be most effective. We also have a variety of clinical trials that will help us find better ways to treat breast cancer. Your medical oncologist will recommend what treatment types and regimens are best for you. The information used to make these decisions include: the location of the cancer, the size of the cancer, the type of cancer, whether the cancer is invasive, the grade of the cancer (a measure of its aggressiveness), prognostic factors such as hormone receptors and HER2 status, and lymph node involvement.
    [Show full text]
  • Evaluation of the Frequency of Patients with Cancer Presenting to an Emergency Department
    ORIGINAL ARTICLE Evaluation of the frequency of patients with cancer presenting to an emergency department Cem Isikber1 Muge Gulen1 Salim Satar2 Akkan Avci1 Selen Acehan1 Gulistan Gul Isikber3 Onder Yesiloglu1 1. Adana City Training and Research Hospital, Department of Emergency Medicine, Adana, Turkey. 2. Associate Professor, Adana City Training and Research Hospital, Department of Emergency Medicine, Adana, Turkey. 3. Adana City Training and Research Hospital, Department of Infectious Diseases and Microbiology, Adana, Turkey. http://dx.doi.org/10.1590/1806-9282.66.10.1402 SUMMARY OBJECTIVE: This study aims to determine the demographic characteristics of cancer patients admitted to an emergency department and determine the relationship between the frequency of admission to the emergency department and oncological emergencies and their effect on mortality. METHODS: This observational, prospective, diagnostic accuracy study was performed in the ED of a tertiary care hospital. Patients over the age of 18 who were previously diagnosed with cancer and admitted to the emergency service for medical reasons were included in the study. We recorded baseline characteristics including age, gender, complaints, oncological diagnosis, metastasis status, cancer treatments received, the number of ED admissions, structural and metabolic oncological emergency diagnoses in the ED, discharge status, length of hospital stay, and mortality status. RESULTS: In our study, 1205 applications related to the oncological diagnosis of 261 patients were examined. 55.6% of the patients were male, and 44.4% were female. The most common metabolic oncological emergency was anemia (19.5%), and the most common structural oncological emergency was bone metastasis-fracture (4.6%.) The mean score of admission of patients to the emergency department was four times (min: 1 max: 29) during the study period.
    [Show full text]
  • Exposure to Carcinogens and Work-Related Cancer: a Review of Assessment Methods
    European Agency for Safety and Health at Work ISSN: 1831-9343 Exposure to carcinogens and work-related cancer: A review of assessment methods European Risk Observatory Report Exposure to carcinogens and work-related cancer: A review of assessment measures Authors: Dr Lothar Lißner, Kooperationsstelle Hamburg IFE GmbH Mr Klaus Kuhl (task leader), Kooperationsstelle Hamburg IFE GmbH Dr Timo Kauppinen, Finnish Institute of Occupational Health Ms Sanni Uuksulainen, Finnish Institute of Occupational Health Cross-checker: Professor Ulla B. Vogel from the National Working Environment Research Centre in Denmark Project management: Dr Elke Schneider - European Agency for Safety and Health at Work (EU-OSHA) Europe Direct is a service to help you find answers to your questions about the European Union Freephone number (*): 00 800 6 7 8 9 10 11 (*) Certain mobile telephone operators do not allow access to 00 800 numbers, or these calls may be billed. More information on the European Union is available on the Internet ( 48TU http://europa.euU48T). Cataloguing data can be found on the cover of this publication. Luxembourg: Publications Office of the European Union, 2014 ISBN: 978-92-9240-500-7 doi: 10.2802/33336 Cover pictures: (clockwise): Anthony Jay Villalon (Fotolia); ©Roman Milert (Fotolia); ©Simona Palijanskaite; ©Kari Rissa © European Agency for Safety and Health at Work, 2014 Reproduction is authorised provided the source is acknowledged. European Agency for Safety and Health at Work – EU-OSHA 1 Exposure to carcinogens and work-related cancer:
    [Show full text]
  • Ovarian Cancer and Cervical Cancer
    What Every Woman Should Know About Gynecologic Cancer R. Kevin Reynolds, MD The George W. Morley Professor & Chief, Division of Gyn Oncology University of Michigan Ann Arbor, MI What is gynecologic cancer? Cancer is a disease where cells grow and spread without control. Gynecologic cancers begin in the female reproductive organs. The most common gynecologic cancers are endometrial cancer, ovarian cancer and cervical cancer. Less common gynecologic cancers involve vulva, Fallopian tube, uterine wall (sarcoma), vagina, and placenta (pregnancy tissue: molar pregnancy). Ovary Uterus Endometrium Cervix Vagina Vulva What causes endometrial cancer? Endometrial cancer is the most common gynecologic cancer: one out of every 40 women will develop endometrial cancer. It is caused by too much estrogen, a hormone normally present in women. The most common cause of the excess estrogen is being overweight: fat cells actually produce estrogen. Another cause of excess estrogen is medication such as tamoxifen (often prescribed for breast cancer treatment) or some forms of prescribed estrogen hormone therapy (unopposed estrogen). How is endometrial cancer detected? Almost all endometrial cancer is detected when a woman notices vaginal bleeding after her menopause or irregular bleeding before her menopause. If bleeding occurs, a woman should contact her doctor so that appropriate testing can be performed. This usually includes an endometrial biopsy, a brief, slightly crampy test, performed in the office. Fortunately, most endometrial cancers are detected before spread to other parts of the body occurs Is endometrial cancer treatable? Yes! Most women with endometrial cancer will undergo surgery including hysterectomy (removal of the uterus) in addition to removal of ovaries and lymph nodes.
    [Show full text]
  • NIH Medlineplus Magazine Winter 2010
    Trusted Health Information from the National Institutes of Health ® NIHMedlineWINTER 2010 Plusthe magazine Plus, in this issue! • Treating “ Keep diverticulitis the beat” Healthy blood Pressure • Protecting Helps Prevent Heart disease Yourself from Shingles • Progress against Prostate cancer • Preventing Suicide in Young Adults • relieving the Model Heidi Klum joins The Heart Truth Pain of tMJ Campaign for women’s heart health. • The Real Benefits of Personalized Prevent Heart Medicine Disease Now! You can lower your risk. A publication of the NatioNal Institutes of HealtH and the frieNds of the NatioNal library of MediciNe FRIENDS OF THE NATIONAL LIBRARY OF MEDICINE Saying “Yes!” to Careers in Health Care ecently, the Friends of NLM was delighted to co-sponsor the fourth annual “Yes, I Can Be a Healthcare Professional” conference at Frederick Douglass Academy in Harlem. More than 2,300 students and parents from socioeconomically disadvantaged communities throughout the entire New York City metropolitan area convened for Rthe daylong session. It featured practical skills workshops, discussion groups, and exhibits from local educational institutions, health professional societies, community health services, and health information providers, including the National Library of Medicine (NLM). If you’ll pardon the expression, the enthusiasm among the attendees—current and future Photo: NLM Photo: healthcare professionals—was infectious! donald West King, M.d. fNlM chairman It was especially exciting to mix with some of the students from six public and charter high schools in Harlem and the South Bronx enrolled in the Science and Health Career Exploration Program. The program was created by Mentoring in Medicine, Inc., funded by the NLM and Let Us Hear co-sponsored by the Friends.
    [Show full text]
  • Front Matter
    ANTICANCER RESEARCH International Journal of Cancer Research and Treatment ISSN: 0250-7005 Volume 36, Number 1, January 2016 Contents Reviews Using Epigenetic Therapy to Overcome Chemotherapy Resistance. J. STRAUSS, W.D. FIGG (Bethesda, MD, USA) ..................................................................................................................................... 1 Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis. A. DEVINE, L. MARIGNOL (Dublin, Ireland) .......................................... 5 Factors Affecting Survival in Patients with Lung Metastases from Colorectal Cancer. A Short Meta-analysis. F. LUMACHI, G.B. CHIARA, R. TOZZOLI, A. DEL CONTEA, S.M.M. BASSO (Padova; Pordenone, Italy)..... 13 TAS-102 an Emerging Oral Fluoropyrimidine. J. CHEN, M. HAN, M.W. SAIF (St. Lucia; Wollongong, Australia; Boston, MA, USA)........................................................................................................... 21 Experimental Studies Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c- RAF and Soluble Epoxide Hydrolase in LSL-KrasG12D/Pdx-1-Cre Mice. J. LIAO, S.H. HWANG, H. LI, J.- Y. LIU, B.D. HAMMOCK, G.-Y. YANG (Chicago, IL; Davis, CA, USA)............................................. 27 HUHS1015 Suppresses Colonic Cancer Growth by Inducing Necrosis and Apoptosis in Association with Mitochondrial Damage. Y. KAKU, A. TSUCHIYA, T. SHIMIZU, A. TANAKA, T. NISHIZAKI (Nishinomiya;
    [Show full text]
  • Download Our Tobacco-Free Resource Guide for Youth
    educate. engage. empower. TOBACCO-FREE COMMUNITY FORUM TOBACCO-FREE RESOURCE GUIDE for Youth, Communities, Parents, and Schools TOBACCO-FREE COMMUNITY FORUM Educate. Engage. Empower. April 28, 2021 This event made possible by the Poe Center for Health Education in partnership with Wake County Human Services, Wake County Public Schools, and the American Heart Association . TOBACCO-FREE COMMUNITY FORUM AGENDA 9:15 a.m. - 9:30 a.m. - Log-In and Sign-On Slideshow of PhotoVoice Projects 9:30 a.m. - 9:40 a.m. - Welcome & Opening Remarks Honorable Sig Hutchinson, Wake County Commissioner Ann Rollins, Executive Director, Poe Center For Health Education Roxie Cash, Wake County Board of Education 9:40 a.m. - 9:45 a.m. - Recognition of Local Champions Presented by Youth Empowerment Team 9:45 a.m. - 10:00 a.m. - A Snapshot of Tobacco’s Impact on Youth In Wake County Sumedh Kotrannavar, Student at Carnage Middle School Teja Wasudev, Student at Cary Academy Nikhil Patel, Student at Enloe High School Gorja Yadav, Student at Enloe High School Lily Zahn, Student at Fuquay-Varina High School 10:00 a.m. - 10:20 a.m. - Latest Updates on Tobacco Impacts, Trends, and Statistics Jim Martin, Director of Policy and Programs with the N.C. Tobacco Prevention and Control Branch Division of Public Health, NC Department of Health and Human Services 10:20 a.m. - 10:45 a.m. - Youth Perspective on Local Tobacco Policy Needs Panel Moderator: Honorable Sig Hutchinson, Wake County Commissioner Panelists: Sumedh Kotrannavar, Student at Carnage Middle School Teja Wasudev, Student at Cary Academy Nikhil Patel, Student at Enloe High School Lily Zahn, Student at Fuquay-Varina High School 10:45 a.m.
    [Show full text]
  • The Use of Rodent Tumors in Experimental Cancer Therapy Conclusions and Recommendations from an International Workshop1'2
    [CANCER RESEARCH 45, 6541-6545, December 1985] Meeting Report The Use of Rodent Tumors in Experimental Cancer Therapy Conclusions and Recommendations from an International Workshop1'2 This workshop was convened to address the question of how of a specific tumor cannot be predicted with any certainty. Virus- best to use animal models of solid tumors in cancer therapy induced rodent tumors almost always express common virus- research. The discussion among the 58 participants focused on coded antigens and are usually strongly immunogenic, but hosts the following topics: appropriate solid tumor models; xenografts neonatally infected with virus may be immunologically tolerant to of human tumors; assay systems such as local tumor control, virus-coded antigens. Chemically induced rodent tumors tend to clonogenic assays following tumor excision, and tumor regrowth express individually distinct antigens. Depending partially upon delay; and applications of such models in chemotherapy, radio the carcinogen and the target organ, the degree of immunoge therapy, and combined modalities studies. nicity is variable, but a large proportion of chemically induced A major goal of the meeting was to produce a set of guiding tumors are immunogenic. Spontaneous rodent tumors are usu principles for experiments on animal tumors. This report is largely ally nonimmunogenic, although a minority may be weakly to a statement of those guiding principles, with suggestions and moderately immunogenic (1, 2). comments concerning investigations using animal models in Because no tumor can be expected to be nonimmunogenic if cancer therapy research.3 The authors believe that this discus it is placed in an allogeneic environment, tumors should as a sion of "tricks of the trade" will be useful to research workers general rule only be transplanted syngeneically.
    [Show full text]
  • Sexual Dysfunction in Gynecologic Cancer Patients
    WCRJ 2017; 4 (1): e835 SEXUAL DYSFUNCTION IN GYNECOLOGIC CANCER PATIENTS L. DEL PUP Division of Gynecological Oncology, CRO Aviano, National Cancer Institute, Aviano (PN), Italy. Abstract – Objective: Sexual dysfunction is prevalent among gynecologic cancer survivors and strongly impacts on the quality of life (QoL), but the subject is poorly diagnosed and treated. Materials and Methods: A comprehensive literature search of English language studies on sex- ual dysfunctions due to gynecologic cancer treatment has been conducted on MEDLINE databases. Results: Surgery, radiation, and chemotherapy can cause any kind of sexual dysfunction with different mechanisms: psychological and relational, hormonal and pharmacological, neurological and vascular, side effects of chemo and radiation therapies, and direct effects of surgery on sexually involved pelvic organs. Many patients expect their healthcare providers to address sexual health concerns, but most have never discussed sex-related issues with their physician, or they do not re- ceive a proper treatment or referral. This can have medical legal consequences, because it must be discussed and documented before starting treatment. Conclusions: Oncology providers can make a significant impact on the QoL of gynecologic cancer sur- vivors by informing patients and by asking them for sexual health concerns. Counseling is per se beneficial, as it improves QoL. Furthermore, it permits a proper referral and resolution of most symptoms. KEYWORDS: Gynecologic cancer, Sexual dysfunction, Vulvar cancer, Vaginal cancer, Cervical cancer, Endometrial cancer, Ovarian cancer, Ospemifene. INTRODUCTION ly ask about sexual issues, but 64% state that phy- sicians never initiates the conversation during their The proportion of people living with and surviv- care3. ing gynecologic cancer is growing.
    [Show full text]